शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
DRREDDYBSEDR. REDDY S LABORATORIES· Pharmaceuticals & BiotechnologyHighNegative
Announced Fri, 7 Aug, 2026 · 22:52 IST

Dr Reddy's ends Novartis India brand distribution pact

Major Contract CancelledBusiness Updates View source PDFExplain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.8%Reaction day
₹1168.60
prior close
₹1172.00
announcement price
After-mkt
timing
Nifty 100market+0.1%-0.9% vs market
Pharmaceuticals peers, median of 165sector-0.1%-0.8% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty 100 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.3
10m
+0.2
15m
+0.1
30m
-0.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.8+0.1-0.9-0.1-0.8
Next day
+3.2-0.3+3.5+0.0+3.2
2d
+2.3-0.4+2.7-0.1+2.4
3d
+3.3-0.6+3.8+0.2+3.1
4d
+2.7-0.7+3.4-0.6+3.3
5d
+2.0-1.0+3.0-1.2+3.2
1w
+0.1-1.8+1.9-2.0+2.1
15d
-1.2-1.9+0.6+0.2-1.4
1m
-2.2-4.2+2.0+1.7-3.9
2m
+5.2-8.9+14.1-2.0+7.3
3m
—————
UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's has terminated its February 2022 agreement with Novartis India Limited for distributing and promoting select brands in India. The termination follows a change in Novartis India's controlling shareholding. Dr. Reddy's will continue to commercialise these brands until 30 September 2026, allowing a transition period.

Likely market impact

Distribution agreement for select brands ends after 30 Sep 2026 transition; may affect future revenue from these brands but smooth handover planned.